MedPath

LUBRIS BIO PTY LTD

🇦🇺Australia
Ownership
-
Employees
-
Market Cap
-
Website

Clinical Trials

4

Active:0
Completed:0

Trial Phases

2 Phases

Phase 1:2
Not Applicable:2

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (4 trials with phase data)• Click on a phase to view related trials

Not Applicable
2 (50.0%)
Phase 1
2 (50.0%)

A PHASE II PROSPECTIVE RANDOMIZED DOUBLE-MASKED CONTROLLED STUDY ASSESSING THE SAFETY & EFFICACY OF RHPRG4 (450 µG/ML RECOMBINANT HUMAN PROTEOGLYCAN 4) COMPARED TO VEHICLE FOR THE TREATMENT OF SJÖGREN'S RELATED DRY EYE DISEASE

Not Applicable
Not yet recruiting
Conditions
Sjögren's Syndrome
Interventions
First Posted Date
2025-08-12
Last Posted Date
2025-08-12
Lead Sponsor
Lubris Bio Pty Ltd
Target Recruit Count
80
Registration Number
NCT07118241
Locations
🇦🇺

Sydney Eye Hospital, Sydney, New South Wales, Australia

🇦🇺

Univ of New South Wales, Sydney, New South Wales, Australia

🇦🇺

OTA, Brisbane, Queensland, Australia

and more 3 locations

A PHASE II PROSPECTIVE RANDOMIZED DOUBLE-MASKED CROSSOVER STUDY ASSESSING THE SAFETY & EFFICACY OF RHPRG4 (450 μG/ML RECOMBINANT HUMAN PROTEOGLYCAN 4) COMPARED TO VEHICLE FOR THE TREATMENT OF OCULAR GRAFT-VERSUS-HOST DISEASE (OGVHD)

Not Applicable
Not yet recruiting
Conditions
Ocular Graft Versus Host Disease
Interventions
Drug: rhPRG4 450ug/ml
Drug: Vehicle Control
First Posted Date
2025-08-12
Last Posted Date
2025-08-12
Lead Sponsor
Lubris Bio Pty Ltd
Target Recruit Count
15
Registration Number
NCT07118254
Locations
🇦🇺

Sydney Eye Hospital, Sydney, New South Wales, Australia

🇦🇺

OTA, Brisbane, Queensland, Australia

🇦🇺

Royal Melbourne Hospital, Melbourne, Victoria, Australia

RHPRG4 FOR THE TREATMENT OF SJÖGREN'S RELATED DRY EYE DISEASE

Phase 1
Not yet recruiting
Conditions
Sjogren's Syndrome With Dry Eye
Interventions
Drug: rhPRG4 (450 µg/mL)
Drug: Vehicle
First Posted Date
2024-07-25
Last Posted Date
2024-07-25
Lead Sponsor
Lubris Bio Pty Ltd
Target Recruit Count
36
Registration Number
NCT06520202

RHPRG4 FOR THE TREATMENT OF OCULAR GRAFT-VERSUS-HOST DISEASE (OGVHD)

Phase 1
Not yet recruiting
Conditions
Ocular Graft-versus-host Disease
Interventions
First Posted Date
2024-07-10
Last Posted Date
2024-07-10
Lead Sponsor
Lubris Bio Pty Ltd
Target Recruit Count
12
Registration Number
NCT06495307

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.